Joseph Baroldi, the Executive Vice President and Chief Business Officer of Ionis Pharmaceuticals (NASDAQ: IONS), reported the sale of 5,619 shares of the company's common stock on April 16, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were sold at a weighted average price of $74.56, producing proceeds of $418,952. Reported sale prices spanned from $74.12 to $75.01.
The filing also shows that on the same date Baroldi had 10,837 shares vest and be released in connection with a Restricted Stock Unit award. Those vested shares were recorded at a price of $0.0 for a reported total value of $0, in line with the mechanics of the award documentation.
The disposition was carried out as an automatic sale to satisfy required tax withholding obligations under the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. After the transactions, the filing states Baroldi directly owns 46,535 shares of Ionis common stock and that his spouse indirectly holds 4,347 shares.
At the time of the reported sale, Ionis shares were trading at $75.71, representing an approximate 167% increase over the trailing 12-month period. Independent analysis cited in the filing, from InvestingPro, characterizes the stock as appearing overvalued relative to its Fair Value. The company also has an earnings report scheduled 12 days out, on April 29, according to the same analysis.
Analyst activity and regulatory context
The Form 4 filing and attendant corporate updates come amid several broker-dealer actions and regulatory milestones related to Ionis' drug Tryngolza. Barclays raised its price target on Ionis to $106 from $95 while maintaining an Overweight rating, a move noted as following the company's announcement of a $40,000 price for Tryngolza. RBC Capital reiterated an Outperform rating with a $95 price target and highlighted the drug's relevance to severe hypertriglyceridemia (sHTG) and familial chylomicronemia syndrome (FCS) indications.
Raymond James initiated coverage of Ionis with an Outperform rating and a $104 price target, citing a stronger-than-expected sHTG readout. H.C. Wainwright reaffirmed a Buy rating and set a $120 price target after regulatory developments in Europe for Tryngolza. The European Medicines Agency validated an indication extension for Tryngolza in severe hypertriglyceridemia, with that action described as supported by data from pivotal Phase 3 trials. William Blair also reiterated an Outperform rating, commenting that the $40,000 wholesale acquisition cost for Tryngolza is higher than originally guided but still lower than a competitor’s listed pricing.
Collectively, these pricing and regulatory updates are presented in filings and commentary as a period of strategic pricing decisions and regulatory progress for Ionis Pharmaceuticals.
What the filings emphasize
- The sale of 5,619 shares was executed at a weighted average price of $74.56 for total proceeds of $418,952, with prices ranging from $74.12 to $75.01.
- Simultaneously, 10,837 restricted stock units vested and were released with a reported price of $0.0 and a total recorded value of $0.
- The share sale was an automatic disposition intended to cover tax withholding obligations under the company's 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
The public filings provide specific ownership figures after the transactions and document the sequence of events without offering commentary on motives beyond the mechanical tax-withholding rationale stated in the agreement.